Evidence for muon neutrino oscillation in an accelerator-based experiment

E. Aliu; S. Andringa; S. Aoki; J. Argyriades; K. Asakura; R. Ashie; H. Berns; H. Bhang; A. Blondel; S. Borghi; J. Bouchez; J. Burguet-Castell; D. Casper; C. Cavata; A. Cervera; K. O. Cho; J. H. Choi; U. Dore; X. Espinal; M. Fechner; E. Fernandez; Y. Fukuda; J. Gomez-Cadenas; R. Gran; T. Hara; M. Hasegawa; T. Hasegawa; K. Hayashi; Y. Hayato; R. L. Helmer; J. Hill; K. Hiraide; J. Hosaka; A. K. Ichikawa; M. Iinuma; A. Ikeda; T. Inagaki; T. Ishida; K. Ishihara; T. Ishii; M. Ishitsuka; Y. Itow; T. Iwashita; H. I. Jang; E. J. Jeon; I. S. Jeong; K. Joo; G. Jover; C. K. Jung; T. Kajita; J. Kameda; K. Kaneyuki; I. Kato; E. Kearns; D. Kerr; C. O. Kim; M. Khabibullin; A. Khotjantsev; D. Kielczewska; J. Y. Kim; S. Kim; P. Kitching; K. Kobayashi; T. Kobayashi; A. Konaka; Y. Koshio; W. Kropp; J. Kubota; Y. Kudenko; Y. Kuno; T. Kutter; J. Learned; S. Likhoded; I. T. Lim; P. F. Loverre; L. Ludovici; H. Maesaka; J. Mallet; C. Mariani; T. Maruyama; S. Matsuno; V. Matveev; C. Mauger; K. McConnel; C. McGrew; S. Mikheyev; A. Minamino; S. Mine; O. Mineev; C. Mitsuda; M. Miura; Y. Moriguchi; T. Morita; S. Moriyama; T. Nakadaira; M. Nakahata; K. Nakamura; I. Nakano; T. Nakaya; S. Nakayama; T. Namba; R. Nambu; S. Nawang; K. Nishikawa; K. Nitta; F. Nova; P. Novella; Y. Obayashi; A. Okada; K. Okumura; S. M. Oser; Y. Oyama; M. Y. Pac; F. Pierre; A. Rodriguez; C. Saji; M. Sakuda; F. Sanchez; A. Sarrat; T. Sasaki; K. Scholberg; R. Schroeter; M. Sekiguchi; E. Sharkey; M. Shiozawa; K. Shiraishi; G. Sitjes; M. Smy; H. Sobel; J. Stone; L. Sulak; A. Suzuki; Y. Suzuki; T. Takahashi; Y. Takenaga; Y. Takeuchi; K. Taki; Y. Takubo; N. Tamura; M. Tanaka; R. Terri; S. T'Jampens; A. Tornero-Lopez; Y. Totsuka; S. Ueda; M. Vagins; C. W. Walter; W. Wang; R. J. Wilkes; S. Yamada; S. Yamamoto; C. Yanagisawa; N. Yershov; H. Yokoyama; M. Yokoyama; J. Yoo; M. Yoshida; J. Zalipska

doi:10.1103/PhysRevLett.94.081802

Evidence for muon neutrino oscillation in an accelerator-based experiment

E. Aliu
, S. Andringa
, S. Aoki
, J. Argyriades
, K. Asakura
, R. Ashie
, H. Berns
, H. Bhang
, A. Blondel
, S. Borghi
, J. Bouchez
, J. Burguet-Castell
, D. Casper
, C. Cavata
, A. Cervera
, K. O. Cho
, J. H. Choi
, U. Dore
, X. Espinal
, M. Fechner

E. Fernandez, Y. Fukuda, J. Gomez-Cadenas, R. Gran, T. Hara, M. Hasegawa, T. Hasegawa, K. Hayashi, Y. Hayato, R. L. Helmer, J. Hill, K. Hiraide, J. Hosaka, A. K. Ichikawa, M. Iinuma, A. Ikeda, T. Inagaki, T. Ishida, K. Ishihara, T. Ishii, M. Ishitsuka, Y. Itow, T. Iwashita, H. I. Jang, E. J. Jeon, I. S. Jeong, K. Joo, G. Jover, C. K. Jung, T. Kajita, J. Kameda, K. Kaneyuki, I. Kato, E. Kearns, D. Kerr, C. O. Kim, M. Khabibullin, A. Khotjantsev, D. Kielczewska, J. Y. Kim, S. Kim, P. Kitching, K. Kobayashi, T. Kobayashi, A. Konaka, Y. Koshio, W. Kropp, J. Kubota, Y. Kudenko, Y. Kuno, T. Kutter, J. Learned, S. Likhoded, I. T. Lim, P. F. Loverre, L. Ludovici, H. Maesaka, J. Mallet, C. Mariani, T. Maruyama, S. Matsuno, V. Matveev, C. Mauger, K. McConnel, C. McGrew, S. Mikheyev, A. Minamino, S. Mine, O. Mineev, C. Mitsuda, M. Miura, Y. Moriguchi, T. Morita, S. Moriyama, T. Nakadaira, M. Nakahata, K. Nakamura, I. Nakano, T. Nakaya, S. Nakayama, T. Namba, R. Nambu, S. Nawang, K. Nishikawa, K. Nitta, F. Nova, P. Novella, Y. Obayashi, A. Okada, K. Okumura, S. M. Oser, Y. Oyama, M. Y. Pac, F. Pierre, A. Rodriguez, C. Saji, M. Sakuda, F. Sanchez, A. Sarrat, T. Sasaki, K. Scholberg, R. Schroeter, M. Sekiguchi, E. Sharkey, M. Shiozawa, K. Shiraishi, G. Sitjes, M. Smy, H. Sobel, J. Stone, L. Sulak, A. Suzuki, Y. Suzuki, T. Takahashi, Y. Takenaga, Y. Takeuchi, K. Taki, Y. Takubo, N. Tamura, M. Tanaka, R. Terri, S. T'Jampens, A. Tornero-Lopez, Y. Totsuka, S. Ueda, M. Vagins, C. W. Walter, W. Wang, R. J. Wilkes, S. Yamada, S. Yamamoto, C. Yanagisawa, N. Yershov, H. Yokoyama, M. Yokoyama, J. Yoo, M. Yoshida, J. Zalipska

Physics & Astronomy (Duluth)

Research output: Contribution to journal › Article › peer-review

424 Scopus citations

Abstract

We present results for ν_μ oscillation in the KEK to Kamioka (K2K) long-baseline neutrino oscillation experiment. K2K uses an accelerator-produced ν_μ beam with a mean energy of 1.3 GeV directed at the Super-Kamiokande detector. We observed the energy-dependent disappearance of v_mu;, which we presume have oscillated to ν_τ. The probability that we would observe these results if there is no neutrino oscillation is 0.0050% (4.0σ).

Original language	English (US)
Article number	081802
Journal	Physical review letters
Volume	94
Issue number	8
DOIs	https://doi.org/10.1103/PhysRevLett.94.081802
State	Published - Mar 4 2005

Bibliographical note

Funding Information:
This work was supported by Gilead Sciences, Inc. Writing support was provided by Impact Communication Partners and funded by Gilead Sciences, Inc.

Funding Information:
Conflict-of-interest disclosure: S.T.O. has served as a consultant for Incyte, Gilead Sciences, Novartis, Celgene/Bristol Myers Squibb, Blueprint Medicines, Kartos Therapeutics, Disc Medicine, and CTI BioPharma. M.T. has received clinical research funding from AbbVie, Novartis, CTI BioPharma, Constellation Pharmaceuticals, Celgene, and NS Pharma. A.T.G. has served as a consultant for CTI BioPharma, Celgene, Kartos Therapeutics, Promedior, and Pfizer. V.G. has served as a consultant for Novartis, Celgene, Sierra Oncology, and Pfizer and has received research funding from Novartis and Incyte. S.V. has received research support for conduct of clinical studies from Incyte, Roche, NS Pharma, Celgene, Gilead Sciences, Promedior, CTI BioPharma, Genentech, Blueprint Medicines, Novartis, Sierra Oncology, Pharma Essentia, AstraZeneca, Ital Pharma, Protagonist Therapeutics, Constellation Pharmaceuticals, Kartos Therapeutics, Prelude Therapeutics, AbbVie, and Telios Pharmaceuticals and has received consulting fees from Constellation Pharmaceuticals, Sierra Oncology, Incyte, Novartis, and Celgene. R.M. has served as a consultant for Novartis, Sierra Oncology, and La Jolla Pharmaceutical and has received research funding from Incyte, CTI BioPharma, Celgene, and Genentech. C.B.M. has served as a consultant for Incyte, Verastem Oncology, and CTI BioPharma. A.G.F. serves on the speaker’s bureau for

Funding Information:
Incyte. M.L.H. has served as a consultant for Blueprint Medicines, Roche, Shire, and Partner Therapeutics and has received research funding from Blueprint Medicine, Bristol Myers Squibb, Constellation Pharmaceuticals, CTI BioPharma, Deciphera Pharmaceuticals, Gilead Sciences, Incyte, Janssen, Novartis, Onconova Therapeutics, and Roche. C.O. has served on an advisory board for AbbVie . M.O.A. has received research funding from Gilead Sciences, Incyte, Janssen, CTI BioPharma, and Samus Therapeutics. T.G. has served as a consultant for Sierra Oncology, Keryx/Akebia, Ionis, Vifor Pharma, American Regent, Silarus Therapeutics, Gossamer Bio, and Disc Medicine; has received research funding from Sierra

Publisher link

10.1103/PhysRevLett.94.081802

Find It

Find It at U of M Libraries

Cite this

Aliu, E., Andringa, S., Aoki, S., Argyriades, J., Asakura, K., Ashie, R., Berns, H., Bhang, H., Blondel, A., Borghi, S., Bouchez, J., Burguet-Castell, J., Casper, D., Cavata, C., Cervera, A., Cho, K. O., Choi, J. H., Dore, U., Espinal, X., ... Zalipska, J. (2005). Evidence for muon neutrino oscillation in an accelerator-based experiment. Physical review letters, 94(8), Article 081802. https://doi.org/10.1103/PhysRevLett.94.081802

Aliu, E, Andringa, S, Aoki, S, Argyriades, J, Asakura, K, Ashie, R, Berns, H, Bhang, H, Blondel, A, Borghi, S, Bouchez, J, Burguet-Castell, J, Casper, D, Cavata, C, Cervera, A, Cho, KO, Choi, JH, Dore, U, Espinal, X, Fechner, M, Fernandez, E, Fukuda, Y, Gomez-Cadenas, J, Gran, R, Hara, T, Hasegawa, M, Hasegawa, T, Hayashi, K, Hayato, Y, Helmer, RL, Hill, J, Hiraide, K, Hosaka, J, Ichikawa, AK, Iinuma, M, Ikeda, A, Inagaki, T, Ishida, T, Ishihara, K, Ishii, T, Ishitsuka, M, Itow, Y, Iwashita, T, Jang, HI, Jeon, EJ, Jeong, IS, Joo, K, Jover, G, Jung, CK, Kajita, T, Kameda, J, Kaneyuki, K, Kato, I, Kearns, E, Kerr, D, Kim, CO, Khabibullin, M, Khotjantsev, A, Kielczewska, D, Kim, JY, Kim, S, Kitching, P, Kobayashi, K, Kobayashi, T, Konaka, A, Koshio, Y, Kropp, W, Kubota, J, Kudenko, Y, Kuno, Y, Kutter, T, Learned, J, Likhoded, S, Lim, IT, Loverre, PF, Ludovici, L, Maesaka, H, Mallet, J, Mariani, C, Maruyama, T, Matsuno, S, Matveev, V, Mauger, C, McConnel, K, McGrew, C, Mikheyev, S, Minamino, A, Mine, S, Mineev, O, Mitsuda, C, Miura, M, Moriguchi, Y, Morita, T, Moriyama, S, Nakadaira, T, Nakahata, M, Nakamura, K, Nakano, I, Nakaya, T, Nakayama, S, Namba, T, Nambu, R, Nawang, S, Nishikawa, K, Nitta, K, Nova, F, Novella, P, Obayashi, Y, Okada, A, Okumura, K, Oser, SM, Oyama, Y, Pac, MY, Pierre, F, Rodriguez, A, Saji, C, Sakuda, M, Sanchez, F, Sarrat, A, Sasaki, T, Scholberg, K, Schroeter, R, Sekiguchi, M, Sharkey, E, Shiozawa, M, Shiraishi, K, Sitjes, G, Smy, M, Sobel, H, Stone, J, Sulak, L, Suzuki, A, Suzuki, Y, Takahashi, T, Takenaga, Y, Takeuchi, Y, Taki, K, Takubo, Y, Tamura, N, Tanaka, M, Terri, R, T'Jampens, S, Tornero-Lopez, A, Totsuka, Y, Ueda, S, Vagins, M, Walter, CW, Wang, W, Wilkes, RJ, Yamada, S, Yamamoto, S, Yanagisawa, C, Yershov, N, Yokoyama, H, Yokoyama, M, Yoo, J, Yoshida, M & Zalipska, J 2005, 'Evidence for muon neutrino oscillation in an accelerator-based experiment', Physical review letters, vol. 94, no. 8, 081802. https://doi.org/10.1103/PhysRevLett.94.081802

@article{feed679a7c95472b84995715a72b61be,

title = "Evidence for muon neutrino oscillation in an accelerator-based experiment",

abstract = "We present results for νμ oscillation in the KEK to Kamioka (K2K) long-baseline neutrino oscillation experiment. K2K uses an accelerator-produced νμ beam with a mean energy of 1.3 GeV directed at the Super-Kamiokande detector. We observed the energy-dependent disappearance of vmu;, which we presume have oscillated to ντ. The probability that we would observe these results if there is no neutrino oscillation is 0.0050\% (4.0σ).",

author = "E. Aliu and S. Andringa and S. Aoki and J. Argyriades and K. Asakura and R. Ashie and H. Berns and H. Bhang and A. Blondel and S. Borghi and J. Bouchez and J. Burguet-Castell and D. Casper and C. Cavata and A. Cervera and Cho, \{K. O.\} and Choi, \{J. H.\} and U. Dore and X. Espinal and M. Fechner and E. Fernandez and Y. Fukuda and J. Gomez-Cadenas and R. Gran and T. Hara and M. Hasegawa and T. Hasegawa and K. Hayashi and Y. Hayato and Helmer, \{R. L.\} and J. Hill and K. Hiraide and J. Hosaka and Ichikawa, \{A. K.\} and M. Iinuma and A. Ikeda and T. Inagaki and T. Ishida and K. Ishihara and T. Ishii and M. Ishitsuka and Y. Itow and T. Iwashita and Jang, \{H. I.\} and Jeon, \{E. J.\} and Jeong, \{I. S.\} and K. Joo and G. Jover and Jung, \{C. K.\} and T. Kajita and J. Kameda and K. Kaneyuki and I. Kato and E. Kearns and D. Kerr and Kim, \{C. O.\} and M. Khabibullin and A. Khotjantsev and D. Kielczewska and Kim, \{J. Y.\} and S. Kim and P. Kitching and K. Kobayashi and T. Kobayashi and A. Konaka and Y. Koshio and W. Kropp and J. Kubota and Y. Kudenko and Y. Kuno and T. Kutter and J. Learned and S. Likhoded and Lim, \{I. T.\} and Loverre, \{P. F.\} and L. Ludovici and H. Maesaka and J. Mallet and C. Mariani and T. Maruyama and S. Matsuno and V. Matveev and C. Mauger and K. McConnel and C. McGrew and S. Mikheyev and A. Minamino and S. Mine and O. Mineev and C. Mitsuda and M. Miura and Y. Moriguchi and T. Morita and S. Moriyama and T. Nakadaira and M. Nakahata and K. Nakamura and I. Nakano and T. Nakaya and S. Nakayama and T. Namba and R. Nambu and S. Nawang and K. Nishikawa and K. Nitta and F. Nova and P. Novella and Y. Obayashi and A. Okada and K. Okumura and Oser, \{S. M.\} and Y. Oyama and Pac, \{M. Y.\} and F. Pierre and A. Rodriguez and C. Saji and M. Sakuda and F. Sanchez and A. Sarrat and T. Sasaki and K. Scholberg and R. Schroeter and M. Sekiguchi and E. Sharkey and M. Shiozawa and K. Shiraishi and G. Sitjes and M. Smy and H. Sobel and J. Stone and L. Sulak and A. Suzuki and Y. Suzuki and T. Takahashi and Y. Takenaga and Y. Takeuchi and K. Taki and Y. Takubo and N. Tamura and M. Tanaka and R. Terri and S. T'Jampens and A. Tornero-Lopez and Y. Totsuka and S. Ueda and M. Vagins and Walter, \{C. W.\} and W. Wang and Wilkes, \{R. J.\} and S. Yamada and S. Yamamoto and C. Yanagisawa and N. Yershov and H. Yokoyama and M. Yokoyama and J. Yoo and M. Yoshida and J. Zalipska",

note = "Funding Information: This work was supported by Gilead Sciences, Inc. Writing support was provided by Impact Communication Partners and funded by Gilead Sciences, Inc. Funding Information: Conflict-of-interest disclosure: S.T.O. has served as a consultant for Incyte, Gilead Sciences, Novartis, Celgene/Bristol Myers Squibb, Blueprint Medicines, Kartos Therapeutics, Disc Medicine, and CTI BioPharma. M.T. has received clinical research funding from AbbVie, Novartis, CTI BioPharma, Constellation Pharmaceuticals, Celgene, and NS Pharma. A.T.G. has served as a consultant for CTI BioPharma, Celgene, Kartos Therapeutics, Promedior, and Pfizer. V.G. has served as a consultant for Novartis, Celgene, Sierra Oncology, and Pfizer and has received research funding from Novartis and Incyte. S.V. has received research support for conduct of clinical studies from Incyte, Roche, NS Pharma, Celgene, Gilead Sciences, Promedior, CTI BioPharma, Genentech, Blueprint Medicines, Novartis, Sierra Oncology, Pharma Essentia, AstraZeneca, Ital Pharma, Protagonist Therapeutics, Constellation Pharmaceuticals, Kartos Therapeutics, Prelude Therapeutics, AbbVie, and Telios Pharmaceuticals and has received consulting fees from Constellation Pharmaceuticals, Sierra Oncology, Incyte, Novartis, and Celgene. R.M. has served as a consultant for Novartis, Sierra Oncology, and La Jolla Pharmaceutical and has received research funding from Incyte, CTI BioPharma, Celgene, and Genentech. C.B.M. has served as a consultant for Incyte, Verastem Oncology, and CTI BioPharma. A.G.F. serves on the speaker{\textquoteright}s bureau for Funding Information: Incyte. M.L.H. has served as a consultant for Blueprint Medicines, Roche, Shire, and Partner Therapeutics and has received research funding from Blueprint Medicine, Bristol Myers Squibb, Constellation Pharmaceuticals, CTI BioPharma, Deciphera Pharmaceuticals, Gilead Sciences, Incyte, Janssen, Novartis, Onconova Therapeutics, and Roche. C.O. has served on an advisory board for AbbVie . M.O.A. has received research funding from Gilead Sciences, Incyte, Janssen, CTI BioPharma, and Samus Therapeutics. T.G. has served as a consultant for Sierra Oncology, Keryx/Akebia, Ionis, Vifor Pharma, American Regent, Silarus Therapeutics, Gossamer Bio, and Disc Medicine; has received research funding from Sierra",

year = "2005",

month = mar,

day = "4",

doi = "10.1103/PhysRevLett.94.081802",

language = "English (US)",

volume = "94",

journal = "Physical review letters",

issn = "0031-9007",

publisher = "American Physical Society",

number = "8",

}

TY - JOUR

T1 - Evidence for muon neutrino oscillation in an accelerator-based experiment

AU - Aliu, E.

AU - Andringa, S.

AU - Aoki, S.

AU - Argyriades, J.

AU - Asakura, K.

AU - Ashie, R.

AU - Berns, H.

AU - Bhang, H.

AU - Blondel, A.

AU - Borghi, S.

AU - Bouchez, J.

AU - Burguet-Castell, J.

AU - Casper, D.

AU - Cavata, C.

AU - Cervera, A.

AU - Cho, K. O.

AU - Choi, J. H.

AU - Dore, U.

AU - Espinal, X.

AU - Fechner, M.

AU - Fernandez, E.

AU - Fukuda, Y.

AU - Gomez-Cadenas, J.

AU - Gran, R.

AU - Hara, T.

AU - Hasegawa, M.

AU - Hasegawa, T.

AU - Hayashi, K.

AU - Hayato, Y.

AU - Helmer, R. L.

AU - Hill, J.

AU - Hiraide, K.

AU - Hosaka, J.

AU - Ichikawa, A. K.

AU - Iinuma, M.

AU - Ikeda, A.

AU - Inagaki, T.

AU - Ishida, T.

AU - Ishihara, K.

AU - Ishii, T.

AU - Ishitsuka, M.

AU - Itow, Y.

AU - Iwashita, T.

AU - Jang, H. I.

AU - Jeon, E. J.

AU - Jeong, I. S.

AU - Joo, K.

AU - Jover, G.

AU - Jung, C. K.

AU - Kajita, T.

AU - Kameda, J.

AU - Kaneyuki, K.

AU - Kato, I.

AU - Kearns, E.

AU - Kerr, D.

AU - Kim, C. O.

AU - Khabibullin, M.

AU - Khotjantsev, A.

AU - Kielczewska, D.

AU - Kim, J. Y.

AU - Kim, S.

AU - Kitching, P.

AU - Kobayashi, K.

AU - Kobayashi, T.

AU - Konaka, A.

AU - Koshio, Y.

AU - Kropp, W.

AU - Kubota, J.

AU - Kudenko, Y.

AU - Kuno, Y.

AU - Kutter, T.

AU - Learned, J.

AU - Likhoded, S.

AU - Lim, I. T.

AU - Loverre, P. F.

AU - Ludovici, L.

AU - Maesaka, H.

AU - Mallet, J.

AU - Mariani, C.

AU - Maruyama, T.

AU - Matsuno, S.

AU - Matveev, V.

AU - Mauger, C.

AU - McConnel, K.

AU - McGrew, C.

AU - Mikheyev, S.

AU - Minamino, A.

AU - Mine, S.

AU - Mineev, O.

AU - Mitsuda, C.

AU - Miura, M.

AU - Moriguchi, Y.

AU - Morita, T.

AU - Moriyama, S.

AU - Nakadaira, T.

AU - Nakahata, M.

AU - Nakamura, K.

AU - Nakano, I.

AU - Nakaya, T.

AU - Nakayama, S.

AU - Namba, T.

AU - Nambu, R.

AU - Nawang, S.

AU - Nishikawa, K.

AU - Nitta, K.

AU - Nova, F.

AU - Novella, P.

AU - Obayashi, Y.

AU - Okada, A.

AU - Okumura, K.

AU - Oser, S. M.

AU - Oyama, Y.

AU - Pac, M. Y.

AU - Pierre, F.

AU - Rodriguez, A.

AU - Saji, C.

AU - Sakuda, M.

AU - Sanchez, F.

AU - Sarrat, A.

AU - Sasaki, T.

AU - Scholberg, K.

AU - Schroeter, R.

AU - Sekiguchi, M.

AU - Sharkey, E.

AU - Shiozawa, M.

AU - Shiraishi, K.

AU - Sitjes, G.

AU - Smy, M.

AU - Sobel, H.

AU - Stone, J.

AU - Sulak, L.

AU - Suzuki, A.

AU - Suzuki, Y.

AU - Takahashi, T.

AU - Takenaga, Y.

AU - Takeuchi, Y.

AU - Taki, K.

AU - Takubo, Y.

AU - Tamura, N.

AU - Tanaka, M.

AU - Terri, R.

AU - T'Jampens, S.

AU - Tornero-Lopez, A.

AU - Totsuka, Y.

AU - Ueda, S.

AU - Vagins, M.

AU - Walter, C. W.

AU - Wang, W.

AU - Wilkes, R. J.

AU - Yamada, S.

AU - Yamamoto, S.

AU - Yanagisawa, C.

AU - Yershov, N.

AU - Yokoyama, H.

AU - Yokoyama, M.

AU - Yoo, J.

AU - Yoshida, M.

AU - Zalipska, J.

N1 - Funding Information: This work was supported by Gilead Sciences, Inc. Writing support was provided by Impact Communication Partners and funded by Gilead Sciences, Inc. Funding Information: Conflict-of-interest disclosure: S.T.O. has served as a consultant for Incyte, Gilead Sciences, Novartis, Celgene/Bristol Myers Squibb, Blueprint Medicines, Kartos Therapeutics, Disc Medicine, and CTI BioPharma. M.T. has received clinical research funding from AbbVie, Novartis, CTI BioPharma, Constellation Pharmaceuticals, Celgene, and NS Pharma. A.T.G. has served as a consultant for CTI BioPharma, Celgene, Kartos Therapeutics, Promedior, and Pfizer. V.G. has served as a consultant for Novartis, Celgene, Sierra Oncology, and Pfizer and has received research funding from Novartis and Incyte. S.V. has received research support for conduct of clinical studies from Incyte, Roche, NS Pharma, Celgene, Gilead Sciences, Promedior, CTI BioPharma, Genentech, Blueprint Medicines, Novartis, Sierra Oncology, Pharma Essentia, AstraZeneca, Ital Pharma, Protagonist Therapeutics, Constellation Pharmaceuticals, Kartos Therapeutics, Prelude Therapeutics, AbbVie, and Telios Pharmaceuticals and has received consulting fees from Constellation Pharmaceuticals, Sierra Oncology, Incyte, Novartis, and Celgene. R.M. has served as a consultant for Novartis, Sierra Oncology, and La Jolla Pharmaceutical and has received research funding from Incyte, CTI BioPharma, Celgene, and Genentech. C.B.M. has served as a consultant for Incyte, Verastem Oncology, and CTI BioPharma. A.G.F. serves on the speaker’s bureau for Funding Information: Incyte. M.L.H. has served as a consultant for Blueprint Medicines, Roche, Shire, and Partner Therapeutics and has received research funding from Blueprint Medicine, Bristol Myers Squibb, Constellation Pharmaceuticals, CTI BioPharma, Deciphera Pharmaceuticals, Gilead Sciences, Incyte, Janssen, Novartis, Onconova Therapeutics, and Roche. C.O. has served on an advisory board for AbbVie . M.O.A. has received research funding from Gilead Sciences, Incyte, Janssen, CTI BioPharma, and Samus Therapeutics. T.G. has served as a consultant for Sierra Oncology, Keryx/Akebia, Ionis, Vifor Pharma, American Regent, Silarus Therapeutics, Gossamer Bio, and Disc Medicine; has received research funding from Sierra

PY - 2005/3/4

Y1 - 2005/3/4

N2 - We present results for νμ oscillation in the KEK to Kamioka (K2K) long-baseline neutrino oscillation experiment. K2K uses an accelerator-produced νμ beam with a mean energy of 1.3 GeV directed at the Super-Kamiokande detector. We observed the energy-dependent disappearance of vmu;, which we presume have oscillated to ντ. The probability that we would observe these results if there is no neutrino oscillation is 0.0050% (4.0σ).

AB - We present results for νμ oscillation in the KEK to Kamioka (K2K) long-baseline neutrino oscillation experiment. K2K uses an accelerator-produced νμ beam with a mean energy of 1.3 GeV directed at the Super-Kamiokande detector. We observed the energy-dependent disappearance of vmu;, which we presume have oscillated to ντ. The probability that we would observe these results if there is no neutrino oscillation is 0.0050% (4.0σ).

UR - https://www.scopus.com/pages/publications/18244367130

UR - https://www.scopus.com/pages/publications/18244367130#tab=citedBy

U2 - 10.1103/PhysRevLett.94.081802

DO - 10.1103/PhysRevLett.94.081802

M3 - Article

AN - SCOPUS:18244367130

SN - 0031-9007

VL - 94

JO - Physical review letters

JF - Physical review letters

IS - 8

M1 - 081802

ER -

Evidence for muon neutrino oscillation in an accelerator-based experiment

Abstract

Bibliographical note

Publisher link

Find It

Other files and links

Fingerprint

Cite this